High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients

Autores
Mandó, Pablo; Rizzo, Manglio Miguel; Roberti, María Paula; Juliá, Estefanía Paula; Pampena, María Betina; de la Puente, Constanza Pérez; Loza, Carlos Martín; Ponce, Carolina; Nadal, Jorge; Coló, Federico Andres; Mordoh, José; Levy, Estrella Mariel
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose: Breast cancer (BC) is a highly heterogeneous disease presenting a broad range of clinical and molecular characteristics. In the past years, a growing body of evidence demonstrated that immune response plays a significant role in cancer outcome. However, immune prognostic markers are not completely validated in clinical practice in BC patients. Materials and methods: With the aim to characterize immune features, several parameters were analyzed in peripheral blood at diagnosis of 85 nonmetastatic BC patients between April 2011 and July 2014. Results: With a median follow-up of 38.6 months, peripheral blood analysis of BC patients (stages I, II, and III) showed that total lymphocyte and T lymphocyte counts were augmented in nonrelapsed patients. Also, a higher neutrophil-to-lymphocytes ratio was associated with prolonged disease-free survival. Natural killer cell receptor analysis revealed that early activation receptor CD69 was associated with a better outcome. Conclusion: This preliminary evidence is in accordance with the concept of immune surveillance. We suggest an “immune phenotype” that provides relevant prognostic information in early-stage BC patients and which could be useful in the decision-making process.
Fil: Mandó, Pablo. Oncology Research Center; Argentina
Fil: Rizzo, Manglio Miguel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Roberti, María Paula. Oncology Research Center; Argentina
Fil: Juliá, Estefanía Paula. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pampena, María Betina. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: de la Puente, Constanza Pérez. Instituto Alexander Fleming; Argentina
Fil: Loza, Carlos Martín. Instituto Alexander Fleming; Argentina
Fil: Ponce, Carolina. Instituto Alexander Fleming; Argentina
Fil: Nadal, Jorge. Instituto Alexander Fleming; Argentina
Fil: Coló, Federico Andres. Instituto Alexander Fleming; Argentina
Fil: Mordoh, José. Oncology Research Center; Argentina
Fil: Levy, Estrella Mariel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
BREAST NEOPLASM
LYMPHOCYTES
NEUTROPHIL-TO-LYMPHOCYTE RATIO
PROGNOSTIC FACTORS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/176567
Acceder
id CONICETDig_f680578a74df89f312e8aab4d9b556cf
oai_identifier_str oai:ri.conicet.gov.ar:11336/176567
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patientsMandó, PabloRizzo, Manglio MiguelRoberti, María PaulaJuliá, Estefanía PaulaPampena, María Betinade la Puente, Constanza PérezLoza, Carlos MartínPonce, CarolinaNadal, JorgeColó, Federico AndresMordoh, JoséLevy, Estrella MarielBREAST NEOPLASMLYMPHOCYTESNEUTROPHIL-TO-LYMPHOCYTE RATIOPROGNOSTIC FACTORShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Purpose: Breast cancer (BC) is a highly heterogeneous disease presenting a broad range of clinical and molecular characteristics. In the past years, a growing body of evidence demonstrated that immune response plays a significant role in cancer outcome. However, immune prognostic markers are not completely validated in clinical practice in BC patients. Materials and methods: With the aim to characterize immune features, several parameters were analyzed in peripheral blood at diagnosis of 85 nonmetastatic BC patients between April 2011 and July 2014. Results: With a median follow-up of 38.6 months, peripheral blood analysis of BC patients (stages I, II, and III) showed that total lymphocyte and T lymphocyte counts were augmented in nonrelapsed patients. Also, a higher neutrophil-to-lymphocytes ratio was associated with prolonged disease-free survival. Natural killer cell receptor analysis revealed that early activation receptor CD69 was associated with a better outcome. Conclusion: This preliminary evidence is in accordance with the concept of immune surveillance. We suggest an “immune phenotype” that provides relevant prognostic information in early-stage BC patients and which could be useful in the decision-making process.Fil: Mandó, Pablo. Oncology Research Center; ArgentinaFil: Rizzo, Manglio Miguel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Roberti, María Paula. Oncology Research Center; ArgentinaFil: Juliá, Estefanía Paula. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pampena, María Betina. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: de la Puente, Constanza Pérez. Instituto Alexander Fleming; ArgentinaFil: Loza, Carlos Martín. Instituto Alexander Fleming; ArgentinaFil: Ponce, Carolina. Instituto Alexander Fleming; ArgentinaFil: Nadal, Jorge. Instituto Alexander Fleming; ArgentinaFil: Coló, Federico Andres. Instituto Alexander Fleming; ArgentinaFil: Mordoh, José. Oncology Research Center; ArgentinaFil: Levy, Estrella Mariel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaDove Press2018-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/176567Mandó, Pablo; Rizzo, Manglio Miguel; Roberti, María Paula; Juliá, Estefanía Paula; Pampena, María Betina; et al.; High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients; Dove Press; OncoTargets and Therapy; 11; 5-2018; 2901-29101178-6930CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961634/pdf/ott-11-2901.pdfinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T12:08:36Zoai:ri.conicet.gov.ar:11336/176567instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 12:08:36.794CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
title High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
spellingShingle High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
Mandó, Pablo
BREAST NEOPLASM
LYMPHOCYTES
NEUTROPHIL-TO-LYMPHOCYTE RATIO
PROGNOSTIC FACTORS
title_short High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
title_full High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
title_fullStr High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
title_full_unstemmed High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
title_sort High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients
dc.creator.none.fl_str_mv Mandó, Pablo
Rizzo, Manglio Miguel
Roberti, María Paula
Juliá, Estefanía Paula
Pampena, María Betina
de la Puente, Constanza Pérez
Loza, Carlos Martín
Ponce, Carolina
Nadal, Jorge
Coló, Federico Andres
Mordoh, José
Levy, Estrella Mariel
author Mandó, Pablo
author_facet Mandó, Pablo
Rizzo, Manglio Miguel
Roberti, María Paula
Juliá, Estefanía Paula
Pampena, María Betina
de la Puente, Constanza Pérez
Loza, Carlos Martín
Ponce, Carolina
Nadal, Jorge
Coló, Federico Andres
Mordoh, José
Levy, Estrella Mariel
author_role author
author2 Rizzo, Manglio Miguel
Roberti, María Paula
Juliá, Estefanía Paula
Pampena, María Betina
de la Puente, Constanza Pérez
Loza, Carlos Martín
Ponce, Carolina
Nadal, Jorge
Coló, Federico Andres
Mordoh, José
Levy, Estrella Mariel
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BREAST NEOPLASM
LYMPHOCYTES
NEUTROPHIL-TO-LYMPHOCYTE RATIO
PROGNOSTIC FACTORS
topic BREAST NEOPLASM
LYMPHOCYTES
NEUTROPHIL-TO-LYMPHOCYTE RATIO
PROGNOSTIC FACTORS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose: Breast cancer (BC) is a highly heterogeneous disease presenting a broad range of clinical and molecular characteristics. In the past years, a growing body of evidence demonstrated that immune response plays a significant role in cancer outcome. However, immune prognostic markers are not completely validated in clinical practice in BC patients. Materials and methods: With the aim to characterize immune features, several parameters were analyzed in peripheral blood at diagnosis of 85 nonmetastatic BC patients between April 2011 and July 2014. Results: With a median follow-up of 38.6 months, peripheral blood analysis of BC patients (stages I, II, and III) showed that total lymphocyte and T lymphocyte counts were augmented in nonrelapsed patients. Also, a higher neutrophil-to-lymphocytes ratio was associated with prolonged disease-free survival. Natural killer cell receptor analysis revealed that early activation receptor CD69 was associated with a better outcome. Conclusion: This preliminary evidence is in accordance with the concept of immune surveillance. We suggest an “immune phenotype” that provides relevant prognostic information in early-stage BC patients and which could be useful in the decision-making process.
Fil: Mandó, Pablo. Oncology Research Center; Argentina
Fil: Rizzo, Manglio Miguel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Roberti, María Paula. Oncology Research Center; Argentina
Fil: Juliá, Estefanía Paula. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pampena, María Betina. Oncology Research Center; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: de la Puente, Constanza Pérez. Instituto Alexander Fleming; Argentina
Fil: Loza, Carlos Martín. Instituto Alexander Fleming; Argentina
Fil: Ponce, Carolina. Instituto Alexander Fleming; Argentina
Fil: Nadal, Jorge. Instituto Alexander Fleming; Argentina
Fil: Coló, Federico Andres. Instituto Alexander Fleming; Argentina
Fil: Mordoh, José. Oncology Research Center; Argentina
Fil: Levy, Estrella Mariel. Instituto Alexander Fleming; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Purpose: Breast cancer (BC) is a highly heterogeneous disease presenting a broad range of clinical and molecular characteristics. In the past years, a growing body of evidence demonstrated that immune response plays a significant role in cancer outcome. However, immune prognostic markers are not completely validated in clinical practice in BC patients. Materials and methods: With the aim to characterize immune features, several parameters were analyzed in peripheral blood at diagnosis of 85 nonmetastatic BC patients between April 2011 and July 2014. Results: With a median follow-up of 38.6 months, peripheral blood analysis of BC patients (stages I, II, and III) showed that total lymphocyte and T lymphocyte counts were augmented in nonrelapsed patients. Also, a higher neutrophil-to-lymphocytes ratio was associated with prolonged disease-free survival. Natural killer cell receptor analysis revealed that early activation receptor CD69 was associated with a better outcome. Conclusion: This preliminary evidence is in accordance with the concept of immune surveillance. We suggest an “immune phenotype” that provides relevant prognostic information in early-stage BC patients and which could be useful in the decision-making process.
publishDate 2018
dc.date.none.fl_str_mv 2018-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/176567
Mandó, Pablo; Rizzo, Manglio Miguel; Roberti, María Paula; Juliá, Estefanía Paula; Pampena, María Betina; et al.; High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients; Dove Press; OncoTargets and Therapy; 11; 5-2018; 2901-2910
1178-6930
CONICET Digital
CONICET
url http://hdl.handle.net/11336/176567
identifier_str_mv Mandó, Pablo; Rizzo, Manglio Miguel; Roberti, María Paula; Juliá, Estefanía Paula; Pampena, María Betina; et al.; High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients; Dove Press; OncoTargets and Therapy; 11; 5-2018; 2901-2910
1178-6930
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961634/pdf/ott-11-2901.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Dove Press
publisher.none.fl_str_mv Dove Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782458202161152
score 12.982451

Publicaciones similares